See more : Chinyang Poly Urethane Co.,Ltd (010640.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Immuneering Corporation (IMRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Immuneering Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Klil Industries Ltd (KLIL.TA) Income Statement Analysis – Financial Results
- IBO Technology Company Limited (2708.HK) Income Statement Analysis – Financial Results
- PT Sari Kreasi Boga Tbk (RAFI.JK) Income Statement Analysis – Financial Results
- Universal Technical Institute, Inc. (UTI) Income Statement Analysis – Financial Results
- JSR Corporation (4185.T) Income Statement Analysis – Financial Results
Immuneering Corporation (IMRX)
About Immuneering Corporation
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 316.95K | 2.08M | 2.31M | 1.92M |
| Cost of Revenue | 764.14K | 158.12K | 1.15M | 1.28M | 1.22M |
| Gross Profit | -764.14K | 158.83K | 926.89K | 1.03M | 696.74K |
| Gross Profit Ratio | 0.00% | 50.11% | 44.56% | 44.61% | 36.29% |
| Research & Development | 41.40M | 36.27M | 26.54M | 15.00M | 4.28M |
| General & Administrative | 16.76M | 15.61M | 8.27M | 3.11M | 2.71M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.76M | 15.61M | 8.27M | 3.11M | 2.71M |
| Other Expenses | 0.00 | 30.05K | -127.06K | 0.00 | 0.00 |
| Operating Expenses | 58.41M | 51.90M | 34.81M | 18.11M | 6.99M |
| Cost & Expenses | 58.41M | 52.06M | 35.97M | 19.39M | 8.21M |
| Interest Income | 3.61M | 1.01M | 169.90K | 42.66K | 57.66K |
| Interest Expense | 0.00 | 1.01M | 0.00 | 0.00 | 351.30K |
| Depreciation & Amortization | 352.08K | 796.79K | 159.07K | 79.31K | 18.08K |
| EBITDA | -58.06M | -51.47M | -33.68M | -17.00M | -7.34M |
| EBITDA Ratio | 0.00% | -16,316.29% | -1,629.17% | -733.74% | -382.35% |
| Operating Income | -58.41M | -51.74M | -33.89M | -17.08M | -6.29M |
| Operating Income Ratio | 0.00% | -16,325.77% | -1,629.17% | -739.01% | -327.71% |
| Total Other Income/Expenses | 4.94M | 1.23M | 42.84K | 42.66K | -1.42M |
| Income Before Tax | -53.47M | -50.51M | -33.84M | -17.04M | -7.71M |
| Income Before Tax Ratio | 0.00% | -15,937.29% | -1,627.11% | -737.17% | -401.59% |
| Income Tax Expense | 0.00 | -1.23M | -307.49K | -84.34K | 351.30K |
| Net Income | -53.47M | -49.28M | -33.54M | -17.04M | -8.06M |
| Net Income Ratio | 0.00% | -15,548.66% | -1,612.33% | -737.17% | -419.89% |
| EPS | -1.88 | -1.87 | -1.27 | -0.67 | -0.32 |
| EPS Diluted | -1.88 | -1.87 | -1.27 | -0.67 | -0.32 |
| Weighted Avg Shares Out | 28.42M | 26.39M | 26.32M | 25.51M | 25.51M |
| Weighted Avg Shares Out (Dil) | 28.42M | 26.39M | 26.32M | 25.51M | 25.51M |
Immuneering to Present at the Morgan Stanley Healthcare Conference
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at...
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
- Positive initial pharmacokinetic, pharmacodynamic and safety data presented at American Association for Cancer Research (AACR) annual meeting, with IMM-1-104 demonstrating Cmax, half-life, and pERK/pMEK suppression consistent with deep cyclic inhibition of the MAPK pathway -
Immuneering Corp.: Early Stage Promise, But Long-Term Investment
IMRX is an early-stage company with promising science. They do not have clinical efficacy data. While I like the company, be warned that this is going to take time.
Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 103.8% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into...
Immuneering to Present at the Jefferies Healthcare Conference
CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at...
Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates
Immuneering Corporation (IMRX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.49 per share a year ago.
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at...
Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains?
Immuneering Corporation (IMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
- Investor call to be held at 9:00 a.m. ET on April 18, 2023 - - Investor call to be held at 9:00 a.m. ET on April 18, 2023 -
Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 102.51%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 102.5% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into...
Source: https://incomestatements.info
Category: Stock Reports